PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-64.40%
Cash & equivalents declining -64.40% while AVXL's grows 194228.00%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
Below half of AVXL's 194228.00%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
Below half of AVXL's 234228.00%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
Below half of AVXL's 522228.00%. Michael Burry sees a potential red flag for stagnation or capital shortage.
289.39%
Less than half of AVXL's -35.42%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Other Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
357.80%
Above 1.5x AVXL's 7.83%. Michael Burry sees a red flag for liquidity risk vs. competitor.
8.45%
Higher Long-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.45%
Higher Total Non-Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
40.87%
Above 1.5x AVXL's 7.83%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-9.75%
Below half AVXL's -53.60%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-29.17%
Higher Other Stockholders' Equity Items Growth compared to AVXL's zero value, indicating worse performance.
-61.26%
Below half AVXL's 20.40%. Michael Burry sees potential underperformance in building shareholder capital.
-64.40%
Below half AVXL's 522228.00%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
8.45%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
24.32%
Less than half of AVXL's 605772.00%. David Dodd sees better deleveraging or stronger cash buildup than competitor.